Australia markets closed

Integra LifeSciences Holdings Corporation (IART)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
59.95-0.54 (-0.89%)
As of 03:31PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.13
52-week change 3-6.52%
S&P500 52-week change 3-7.13%
52-week high 368.29
52-week low 340.67
50-day moving average 356.28
200-day moving average 353.83

Share statistics

Avg vol (3-month) 3453.33k
Avg vol (10-day) 3411.97k
Shares outstanding 583.52M
Implied shares outstanding 6N/A
Float 872.51M
% held by insiders 113.01%
% held by institutions 191.71%
Shares short (12 Jan 2023) 43.85M
Short ratio (12 Jan 2023) 47.83
Short % of float (12 Jan 2023) 46.14%
Short % of shares outstanding (12 Jan 2023) 44.61%
Shares short (prior month 14 Dec 2022) 44.01M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 303 Jan 2017

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 11.05%
Operating margin (ttm)17.43%

Management effectiveness

Return on assets (ttm)4.50%
Return on equity (ttm)10.31%

Income statement

Revenue (ttm)1.57B
Revenue per share (ttm)18.76
Quarterly revenue growth (yoy)-0.40%
Gross profit (ttm)976.97M
EBITDA 392.39M
Net income avi to common (ttm)172.99M
Diluted EPS (ttm)2.11
Quarterly earnings growth (yoy)15.50%

Balance sheet

Total cash (mrq)525.05M
Total cash per share (mrq)6.29
Total debt (mrq)1.71B
Total debt/equity (mrq)99.42
Current ratio (mrq)3.93
Book value per share (mrq)20.65

Cash flow statement

Operating cash flow (ttm)248.41M
Levered free cash flow (ttm)178.36M